Diener Hans-Christoph, Dowson Andrew, Whicker Susan, Bacon Teresa
Department of Neurology, University Hospital Essen, Essen, Germany.
J Headache Pain. 2008 Dec;9(6):359-65. doi: 10.1007/s10194-008-0070-6. Epub 2008 Oct 25.
A questionnaire (Migraine Questionnaire; MQ) was developed to help pharmacists identify consumers with migraine suitable for non-prescription treatment with a triptan. Adults, who knew or thought that they had migraine, participated in three, sequential, community-based studies to validate the MQ. Overall, 1,353 subjects completed independent assessments with a pharmacist and a clinician (reference standard). The accuracy of the pharmacist assessment of suitability for a triptan was compared with the clinician assessment. Clinicians using their standard practice determined that triptan therapy was suitable in 76.8% of cases compared with 48.8% for pharmacists using the MQ. The lack of concordance between pharmacists and clinicians in the false-positive cases (n = 113 of 660 subjects considered suitable for triptan by the pharmacists) usually related to headache diagnosis (57.5%), not safety aspects. The MQ is an effective tool for pharmacists to guide appropriate recommendation of a non-prescription triptan for migraine.
开发了一份问卷（偏头痛问卷；MQ），以帮助药剂师识别适合使用曲坦类药物进行非处方治疗的偏头痛患者。知晓或认为自己患有偏头痛的成年人参与了三项基于社区的连续研究，以验证该MQ。总体而言，1353名受试者接受了药剂师和临床医生（参考标准）的独立评估。将药剂师对使用曲坦类药物适用性的评估准确性与临床医生的评估进行了比较。临床医生按照其标准做法确定，76.8%的病例适合使用曲坦类药物治疗，而使用MQ的药剂师确定的比例为48.8%。在假阳性病例中（药剂师认为适合使用曲坦类药物的660名受试者中有113例），药剂师和临床医生之间缺乏一致性，这通常与头痛诊断（57.5%）有关，而非安全性方面。MQ是药剂师指导偏头痛非处方曲坦类药物合理推荐的有效工具。
